ATAD3A on the path to cancer

Yong Teng; Liwei Lang; Chloe Shay

doi:10.1007/978-3-030-12668-1_14

ATAD3A on the path to cancer

Yong Teng, Liwei Lang, Chloe Shay

Oral Biology & Dx Sciences

Research output: Chapter in Book/Report/Conference proceeding › Chapter

12 Scopus citations

Abstract

The ATPase family AAA-domain containing protein 3A (ATAD3A), a nuclear-encoded mitochondrial enzyme, is involved in diverse cellular processes, including mitochondrial dynamics, cell death and cholesterol metabolism. Overexpression and/or mutation of the ATAD3A gene have been observed in different types of cancer, associated with cancer development and progression. The dysregulated ATAD3A acts as a broker of a mitochondria-endoplasmic reticulum connection in cancer cells, and inhibition of this enzyme leads to tumor repression and enhanced sensitivity to chemotherapy and radiation. As such, ATAD3A is a promising drug target in cancer treatment.

Original language	English (US)
Title of host publication	Advances in Experimental Medicine and Biology
Publisher	Springer New York LLC
Pages	259-269
Number of pages	11
DOIs	https://doi.org/10.1007/978-3-030-12668-1_14
State	Published - 2019

Publication series

Name	Advances in Experimental Medicine and Biology
Volume	1134
ISSN (Print)	0065-2598
ISSN (Electronic)	2214-8019

Keywords

ATAD3A
Cancer treatment
Drug target
Mitochondria
Oncogene

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-3-030-12668-1_14

Cite this

@inbook{a011aa0624e741dc992d2bc5b913f67d,

title = "ATAD3A on the path to cancer",

abstract = "The ATPase family AAA-domain containing protein 3A (ATAD3A), a nuclear-encoded mitochondrial enzyme, is involved in diverse cellular processes, including mitochondrial dynamics, cell death and cholesterol metabolism. Overexpression and/or mutation of the ATAD3A gene have been observed in different types of cancer, associated with cancer development and progression. The dysregulated ATAD3A acts as a broker of a mitochondria-endoplasmic reticulum connection in cancer cells, and inhibition of this enzyme leads to tumor repression and enhanced sensitivity to chemotherapy and radiation. As such, ATAD3A is a promising drug target in cancer treatment.",

keywords = "ATAD3A, Cancer treatment, Drug target, Mitochondria, Oncogene",

author = "Yong Teng and Liwei Lang and Chloe Shay",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2019.",

year = "2019",

doi = "10.1007/978-3-030-12668-1_14",

language = "English (US)",

series = "Advances in Experimental Medicine and Biology",

publisher = "Springer New York LLC",

pages = "259--269",

booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - ATAD3A on the path to cancer

AU - Teng, Yong

AU - Lang, Liwei

AU - Shay, Chloe

N1 - Publisher Copyright: © Springer Nature Switzerland AG 2019.

PY - 2019

Y1 - 2019

N2 - The ATPase family AAA-domain containing protein 3A (ATAD3A), a nuclear-encoded mitochondrial enzyme, is involved in diverse cellular processes, including mitochondrial dynamics, cell death and cholesterol metabolism. Overexpression and/or mutation of the ATAD3A gene have been observed in different types of cancer, associated with cancer development and progression. The dysregulated ATAD3A acts as a broker of a mitochondria-endoplasmic reticulum connection in cancer cells, and inhibition of this enzyme leads to tumor repression and enhanced sensitivity to chemotherapy and radiation. As such, ATAD3A is a promising drug target in cancer treatment.

AB - The ATPase family AAA-domain containing protein 3A (ATAD3A), a nuclear-encoded mitochondrial enzyme, is involved in diverse cellular processes, including mitochondrial dynamics, cell death and cholesterol metabolism. Overexpression and/or mutation of the ATAD3A gene have been observed in different types of cancer, associated with cancer development and progression. The dysregulated ATAD3A acts as a broker of a mitochondria-endoplasmic reticulum connection in cancer cells, and inhibition of this enzyme leads to tumor repression and enhanced sensitivity to chemotherapy and radiation. As such, ATAD3A is a promising drug target in cancer treatment.

KW - ATAD3A

KW - Cancer treatment

KW - Drug target

KW - Mitochondria

KW - Oncogene

UR - http://www.scopus.com/inward/record.url?scp=85063935448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063935448&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-12668-1_14

DO - 10.1007/978-3-030-12668-1_14

M3 - Chapter

C2 - 30919342

AN - SCOPUS:85063935448

T3 - Advances in Experimental Medicine and Biology

SP - 259

EP - 269

BT - Advances in Experimental Medicine and Biology

PB - Springer New York LLC

ER -

ATAD3A on the path to cancer

Abstract

Publication series

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this